Diversified Trust’s Fortress Biotech FBIO Stock Holding History

Diversified Trust’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-867	Closed	-$53K	–	753
2020 Q3	$53K	Buy	+867	New	+$44.2K	﹤0.01%	631

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SAM

Shikiar Asset Management New York $347M AUM 23.44% 1-Year Est. Return

Diversified Trust's FBIO Position: Q4 2020 in Review

Diversified Trust sold out of Fortress Biotech (FBIO) in Q4 2020, closing a stake of 867 shares — an estimated $53K sold.

Diversified Trust first reported a position in FBIO in Q3 2020 and held it in 1 quarter. The position peaked at $53K in Q3 2020. 87 funds tracked by Wall St. Rank hold FBIO as of Q4 2020.

Diversified Trust reported no remaining Fortress Biotech position as of Q4 2020 after selling out during the quarter.
Diversified Trust sold 867 Fortress Biotech shares in Q4 2020, an estimated $53K.
Diversified Trust first reported a position in Fortress Biotech in Q3 2020 and held it in 1 quarter.
Diversified Trust's Fortress Biotech position peaked at $53K in Q3 2020.
87 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2020.

Based on Diversified Trust's 13F filing for Q4 2020, filed 8 Jan 2021.